AQP4 autoantibody assay performance in clinical laboratory service
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 20, 2014
- Accepted in final form March 31, 2014
- First Published May 22, 2014.
Author Disclosures
- J.P. Fryer, MS,
- V.A. Lennon, MD, PhD,
- S.J. Pittock, MD,
- S.M. Jenkins, MS,
- P. Fallier-Becker, PhD,
- S.L. Clardy, MD, PhD,
- E. Horta, MD,
- E.A. Jedynak, BS,
- C.F. Lucchinetti, MD,
- E.A. Shuster, MD,
- B.G. Weinshenker, MD,
- D.M. Wingerchuk, MD and
- A. McKeon, MD
- J.P. Fryer, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- V.A. Lennon, MD, PhD,
NONE
NONE
NONE
NONE
Dr. Lennon and Mayo Clinic have a financial interest in the following intellectual property:
NONE
NONE
NONE
NONE
NONE
Dr. Lennon is Director of the Mayo Neuroimmunology Laboratory that performs service testing for aquaporin-4 autoantibodies on behalf of Mayo Collaborative Service Inc., an agency of Mayo Foundation. Neither Dr. Lennon nor her laboratory benefit financially from this testing.
NONE
NIH R01-NS065829,�CNS Demyelinating Autoimmunity Targeting Water Channel Complexes�. Principal Investigator: S.J. Pittock Co-Investigator: V.A. Lennon Years: 2010-2015
NONE
NONE
NONE
NONE
Dr. Lennon has a potential financial interest in the technologies listed below:
NONE
NONE
NONE
- S.J. Pittock, MD,
NONE
NONE
NONE
NONE
Dr. Pittock and Mayo Clinic have a financial interest in the technology entitled
NONE
NONE
Dr. Pittock has provided consultation to Alexion Pharmaceuticals, Medimmune and Chugai Pharma USA but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic.
NONE
NONE
NONE
Dr. Pittock has received a research grant from Alexion pharmaceuticals for his investigator-initiated study entitled
RO1 NS065829-01 entitled �CNS Demyelinating Autoimmunity Targeting Water Channel Complexes�
NONE
Guthy Jackson Charitable Foundation grant for NMO research
NONE
NONE
NONE
NONE
NONE
NONE
- S.M. Jenkins, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- P. Fallier-Becker, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- S.L. Clardy, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- E. Horta, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Multiple Sclerosis International Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- E.A. Jedynak, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- C.F. Lucchinetti, MD,
(1)Member NIH/NINDS CNBT Study Section
NONE
Biogen Idec, travel expense reimbursement, to present at their offices on May 10, 2013; honorarium and travel reimbursement to present on March 31, 2014
NONE
(1) patent re: aquaporin-4 associated antibodies for diagnosis of neuromyelitis optica
(1)Blue Books of Neurology: Multiple Sclerosis 3 (Saunders Elsevier, 2010)
NONE
Biogen Idec, 5-10-2013, travel reimbursement only Biogen Idec, 3-31-2014 travel reimb and honorarium
NONE
NONE
NONE
NONE
(1) NIH R01 NS049577-04: �Mechanisms of Multiple Sclerosis Tissue Pathology�(4/09-3/13) (2) NIH: 2P50 NS038667-11 �Tissue injury and inflammation in MS� Principal Investigator: Ransohoff RM (Cleveland Clinic Foundation); Co-Leader, Project 1 (Chemokines and chemokine receptors in MS): Lucchinetti CF. Category I: 5% (12/01/09-11/30/14). DoD (Co-investigator) Cortical Lesions as Determinants of White Matter Lesion Formation and Cognitive Abnormalities in MS 9/2013-8/2015
NONE
(1) National Multiple Sclerosis Society: Multiple Sclerosis Lesion Project, RG3185-B-3. (No-cost extension) Principal Investigator: Lucchinetti CF. (4/1/05-9/30/10).(2)Guthy Jackson Charitable Foundation FP00052074 �Development and Validation of Aquaporin Autoimmunity Models� Principal Investigator: Lennon VA; Co-investigator: Lucchinetti CF. Category I: 8% (10/1/08- 09/30/11). (3) Guthy-Jackson Charitable Foundation, Synergistic Interactions between Astrocytes, Eosinophils and AQP4-IgG in NMO. ( 07/01/10 � 06/30/14)
NONE
NONE
(1) aquaporin-4 associated antibodies for diagnosis of neuromyelitis optica;
NONE
NONE
NONE
- E.A. Shuster, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
PRIME, Inc., educational event, September, 2012. Personal compensation.
NONE
NONE
NONE
NONE
National Multiple Sclerosis Society
NONE
NONE
NONE
NONE
NONE
NONE
- B.G. Weinshenker, MD,
(1) Novartis data safety monitoring board member (2) Biogen Idec data safety monitoring board member (3) Mitsubishi Pharmaceuticals data safety monitoring board member
NONE
NONE
1. Canadian Journal of Neurological Sciences, editorial board member, 2006-present; no compensation 2. Turkish Journal of Neurology, editorial board member, 2005-present; no compensation 3. Neurology, editorial board member, 2014-present; no compensation
1) NMO-IgG for diagnosis of neuromyelitis optica; application 20050112116; patent issued and technology licensed to R.S.R. Ltd.
NONE
NONE
(1) Elan Pharmaceuticals (2) GlaxoSmithKline Pharmaceuticals (3) Ono Pharmaceuticals (4) Asahi Kasei Medical Company (5) Chugai Pharmaceuticals (6) Alexion Pharmaceuticals (7) Chord Pharmaceuticals
NONE
(1)Medimmune Pharmaceuticals, Adjudication Committee Member
NONE
NONE
NONE
NONE
Guthy Jackson Charitable Foundation, sponsor of research in NMO, 10/2008-09/2011
NONE
NONE
NMO-IgG for diagnosis of neuromyelitis optica; patent issued and technology licensed to R.S.R. Ltd.
NONE
NONE
NONE
- D.M. Wingerchuk, MD and
(1) Adjudication committee for therapeutic trial, MedImmune
NONE
NONE
(1) Current Medical Research and Opinion, Editorial Advisory Board member, 2006-present (2) Drugs in Context, Editorial Advisory Board Member, 2012-present
NONE
NONE
NONE
(1)Alexion, (2) Chugai Pharmaceuticals,(3) MedImmune
NONE
NONE
NONE
(1) Genzyme,(2) Alexion,(3) TerumoBCT
NONE
NONE
(1) National Multiple Sclerosis Society (2) Guthy-Jackson Charitable Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- A. McKeon, MD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Medimmune, Inc
NONE
NONE
Guthy Jackson Charitable Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- From the Departments of Laboratory Medicine and Pathology (J.P.F., V.A.L., S.J.P., E.H., E.A.J., A.M.), Neurology (V.A.L., S.J.P., S.L.C., C.F.L., B.G.W., A.M.), Immunology (V.A.L.), and Health Sciences Research (S.M.J.), College of Medicine, Mayo Clinic, Rochester, MN; Institute of Pathology and Neuropathology (P. F.-B.), University of Tubingen, Germany; Department of Neurology (E.A.S.), College of Medicine, Mayo Clinic, Jacksonville, FL; and Department of Neurology (D.M.W.), College of Medicine, Mayo Clinic, Scottsdale, AZ.
- Correspondence to Dr. McKeon: mckeon.andrew{at}mayo.edu
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.